Wei Tian
- Sensory Systems top 10%
-
- Cancer Immunotherapy and Biomarkers 5
- Pancreatic and Hepatic Oncology Research 4
- Peptidase Inhibition and Analysis 3
- Biotechnology top 10%
- Cancer Research and Treatments 3
-
- Ubiquitin and proteasome pathways 4
- Retinoids in leukemia and cellular processes 3
-
- Nanoplatforms for cancer theranostics 4
-
- Estrogen and related hormone effects 3
- Journals
- American Journal of Physiology-Renal Physiology (4 papers)Oncotarget (2 papers)Proceedings of the National Academy of Sciences (2 papers)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Wei Tian
44 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 95
- Sensory Systems 46
- Cancer Research 135
- Oncology 202
- Biotechnology 62
- Molecular Biology 487
Countries citing papers authored by Wei Tian
This map shows the geographic impact of Wei Tian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Tian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Tian more than expected).
Fields of papers citing papers by Wei Tian
This network shows the impact of papers produced by Wei Tian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Tian. The network helps show where Wei Tian may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Wei Tian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 4 | |
| 4 | 2024 | 7 | |
| 5 | 2024 | 5 | |
| 6 | 2024 | 7 | |
| 7 | 2023 | 1 | |
| 8 | 2021 | 17 | |
| 9 | 2021 | 1 | |
| 10 | 2020 | 2 | |
| 11 | 2019 | 71 | |
| 12 | 2019 | 3 | |
| 13 | 2018 | 40 | |
| 14 | 2016 | 48 | |
| 15 | 2014 | 38 | |
| 16 | 2013 | 6 | |
| 17 | 2013 | 30 | |
| 18 | 2009 | 79 | |
| 19 | 2004 | 21 | |
| 20 | SIGNIFICATION OF PERIPHERAL BLOOD IMMUNE CHANGES IN TREATMENT FOR ORAL CANCER WITH (HAS) AND CHEMOTHERAPY | 2001 | 1 |
About Wei Tian
Wei Tian is a scholar working on Oncology, Biological Psychiatry and Cancer Research, having authored 48 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (5 papers), Pancreatic and Hepatic Oncology Research (4 papers), Ubiquitin and proteasome pathways (4 papers), Nanoplatforms for cancer theranostics (4 papers), Peptidase Inhibition and Analysis (3 papers), Retinoids in leukemia and cellular processes (3 papers), Cancer Research and Treatments (3 papers) and Estrogen and related hormone effects (3 papers). The work is most often cited by research in Sensory Systems (46 citations), Cancer Research (135 citations) and Oncology (202 citations). Wei Tian has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include David Cohen, Zheng Zhang, Siyu Chen, Wenping Ding, Tiesuo Zhao, Huijie Jia, Lian Zhang, Yingying Tong, Zhiwei Feng and Jing Guo. Their work appears in journals such as American Journal of Physiology-Renal Physiology, Oncotarget, Proceedings of the National Academy of Sciences, International Immunopharmacology and Acta Biochimica et Biophysica Sinica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.